Pancreatic Cancer Research

Clinical trialPhase 4Completed

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

NCT00966277↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 4
Status
Completed
Study type
Interventional
Start
April 2010
Expected end
September 2014
Enrollment
87 participants
Sites
1
Primary outcomes
Number of Participants With Venous Thromboembolic Events (VTE)
Sponsor
Other
Results posted
2016-12-12
Last update
12 December 2016

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants With Venous Thromboembolic Events (VTE) [16 weeks of treatment]. Number, participants. Group 1: Dalteparin (n=38): 2; Group 2: Control (n=37): 9.

Papers 3